| According to Qichacha, on December 8,Wuhan Mindray ScientificCompleted Series A financing, with Mindray Medical taking over from Mindray Technology Holdings to become the largest shareholder of Wuhan Mindray. Meanwhile, the registered capital of Wuhan Mindray...Increased from 300 million yuan to 2.3 billion yuan。At the same time, the legal representative of Wuhan Mindray Scientific Co., Ltd. has been changed from Shi Peng to Han Le, which also means that the management team of Wuhan Mindray will undergo significant changes.Wuhan Mindray Scientific Co., Ltd. is headquartered in Wuhan and specializes in the development and research of orthopedic consumables and medical devices.Previously, Wuhan Mindray Biomedical Technology Co., Ltd., as Mindray's global second headquarters base, invested over 4.5 billion yuan. It has now been deregistered, indicating that it has merged with Wuhan Mindray Scientific Co., Ltd. Moving forward, Mindray will integrate resources in Wuhan and operate under Wuhan Mindray Scientific Co., Ltd.Mindray's Wuhan Base, with a Total Investment of 4.5 Billion Yuan and a Total Construction Area of Approximately 530,000 Square Meters, Includes Two Sub-Projects: The Wuhan Research Institute and The Manufacturing Base. It is Mindray's Second Global Headquarters Base after Shenzhen.Among them, the construction content of the Wuhan Research Institute project is biomedical engineering research and development, including the research and development of biological raw materials and reagents, surgical equipment research and development, large health technology research and development, etc., positioned as an ultra-large research and development center; the construction content of the Wuhan production and manufacturing base project includes the production, manufacturing, and business services of medical equipment and biological raw materials.The Wuhan base has been subject to several additional investments by Mindray.In 2019, Mindray Medical planned to increase its investment in the Wuhan Research Institute, and finally passed the resolution to increase investment on June 19, 2020. The company estimated that the total investment of Mindray Medical Wuhan Production Base Project and Wuhan Research Institute Project would not exceed RMB 4.5 billion.In June 2021, Mindray announced that it agreed to reduce the amount of funds raised for the "Marketing Service System Upgrade Project" and the "Information System Construction Project". The reduced funds from these projects, along with the remaining funds from the "R&D Innovation Platform Upgrade Project" and the "Mindray Nanjing Bioreagent Manufacturing Center Construction Project", will be redirected to the construction of the "Wuhan Research Institute Project". | 
